Kyowa Hakko Kirin Co., Ltd. announced consolidated and non-consolidated financial results for the year ended December 31, 2015. For the year, on consolidated basis, the company reported net sales of ¥364,316 million against ¥333,446 million a year ago. Operating income was ¥43,765 million against ¥36,173 million a year ago. Income before income taxes and minority interests was ¥41,400 million against ¥27,245 million a year ago. Net income was ¥29,774 million against ¥15,898 million a year ago. Net cash provided by operating activities was ¥66,526 million compared to ¥19,377 million a year ago. Purchase of property, plant and equipment was ¥19,058 million compared to ¥30,466 million a year ago. Purchase of intangible assets was ¥1,038 million compared to ¥4,186 million a year ago. Fully diluted earnings per share were ¥54.36 compared to ¥29.02 a year ago. Consolidated net sales and operating income increased due mainly to the growth in sales of new products as well as the impact of Archimedes Pharma Limited, which was acquired in August 2014Net income respectively increased due to the increase in operating income. Return on equity was 4.9% compared to 2.7% a year ago.

For the year, on non-consolidated basis, the company reported net sales of ¥217,949 million against ¥201,791 million a year ago. Operating income was ¥39,931 million against ¥35,050 million a year ago. Net income was ¥40,241 million against ¥31,500 million a year ago. Fully diluted earnings per share were ¥73.47 compared to ¥57.51 a year ago.

For the six months ending June 30, 2016, on consolidated basis, the company expects net sales of ¥171,000 million, operating income of ¥9,000 million.

For the year ending December 31, 2016, on consolidated basis, the company expects net sales of ¥351,000 million, operating income of ¥30,000 million, profit attributable to owners of parent of ¥16,000 million.